Lilly reports first-quarter 2025 financial results and highlights pipeline momentum

Core Insights - Eli Lilly and Company reported a strong financial performance in Q1 2025, with a 45% year-over-year revenue growth driven by robust sales of Mounjaro and Zepbound [2][3][7] - The company is investing in manufacturing to meet global demand for its new medicines, including plans to build four new facilities [2][19] - The pipeline continues to show promise with recent product approvals in oncology and immunology, and positive Phase 3 trial results for orforglipron in diabetes and obesity [2][19] Financial Results - Total revenue for Q1 2025 was $12.73 billion, a 45$8.77 billion in Q1 2024, primarily due to a 53% increase in volume [3][7] - Net income for Q1 2025 was $2.76 billion, up 23$2.24 billion in Q1 2024, with reported earnings per share (EPS) increasing to $3.06 from$2.48 [11][36] - Non-GAAP net income was $3.00 billion, a 29$2.34 billion in Q1 2024, with non-GAAP EPS rising to $3.34 from$2.58 [13][36] Revenue Breakdown - U.S. revenue increased by 49% to $8.49 billion, driven by a 57$4.24 billion, with a 46% increase in volume, primarily from Mounjaro and Jardiance [5][7] - Mounjaro revenue surged 113% to $3.84 billion, while Zepbound revenue reached$2.31 billion, up from $517.4 million in Q1 2024 [16][17] Cost and Margin Analysis - Gross margin increased 48$10.50 billion, with a gross margin percentage of 82.5%, up 1.6 percentage points from the previous year [6][11] - Research and development expenses rose 8% to $2.73 billion, representing 21.5$2.47 billion [8][11] Guidance and Future Outlook - The company reaffirmed its 2025 revenue guidance of $58.0 billion to$61.0 billion, with an expected performance margin of 40.5% to 42.5% on a reported basis [20][22] - The effective tax rate for 2025 is projected to be around 17%, up from approximately 16% [21][22] - EPS guidance for 2025 has been adjusted to a range of $20.17 to$21.67 on a reported basis, reflecting the impact of acquired IPR&D charges [22][23]